Advances in the pharmacotherapy of patients with acromegaly

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Acromegaly is a disease characterized by growth hormone (GH) excess originating, in approximately 95% of cases, from a somatotroph pituitary adenoma. Symptomatology and clinical features are due to GH and insulin-like growth factor 1 excess; unfortunately, for most patients diagnosis is delayed by several years. Acromegaly patients' morbidity and mortality are higher than those of the normal population. However, with adequate biochemical control mortality rates can be restored to normal. Tumor size and location, symptoms, comorbidities, and lastly, but not least, patient preference, are all important aspects in treatment decision making, and treatment approach should be individualized. Current therapy includes medical, surgical, and radiation. This review focuses on recent significant developments in medical therapy. There are three major therapeutic drug classes: somatostatin receptor ligands (SRLs), which represent the mainstay of medical therapy, GH receptor blockers, and dopamine agonists. Multi-ligand receptor SRLs such as pasireotide, should increase therapeutic choices for acromegaly patients currently uncontrolled on available SRLs. Furthermore, significant research has been focused in the development of novel delivery modalities (e.g., oral and long acting subcutaneous administration).

Original languageEnglish (US)
Pages (from-to)329-338
Number of pages10
JournalDiscovery medicine
Volume17
Issue number96
StatePublished - 2014

Fingerprint

Acromegaly
Drug Therapy
Somatostatin Receptors
Ligands
Therapeutics
Growth Hormone-Secreting Pituitary Adenoma
Somatotropin Receptors
Mortality
Patient Preference
Delayed Diagnosis
Dopamine Agonists
Pituitary Neoplasms
Somatomedins
Growth Hormone
Comorbidity
Decision Making
Hormones
Radiation
Morbidity
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Advances in the pharmacotherapy of patients with acromegaly. / Fleseriu, Maria.

In: Discovery medicine, Vol. 17, No. 96, 2014, p. 329-338.

Research output: Contribution to journalArticle

@article{b6317cfd81444ad3a5761dcad2378835,
title = "Advances in the pharmacotherapy of patients with acromegaly",
abstract = "Acromegaly is a disease characterized by growth hormone (GH) excess originating, in approximately 95{\%} of cases, from a somatotroph pituitary adenoma. Symptomatology and clinical features are due to GH and insulin-like growth factor 1 excess; unfortunately, for most patients diagnosis is delayed by several years. Acromegaly patients' morbidity and mortality are higher than those of the normal population. However, with adequate biochemical control mortality rates can be restored to normal. Tumor size and location, symptoms, comorbidities, and lastly, but not least, patient preference, are all important aspects in treatment decision making, and treatment approach should be individualized. Current therapy includes medical, surgical, and radiation. This review focuses on recent significant developments in medical therapy. There are three major therapeutic drug classes: somatostatin receptor ligands (SRLs), which represent the mainstay of medical therapy, GH receptor blockers, and dopamine agonists. Multi-ligand receptor SRLs such as pasireotide, should increase therapeutic choices for acromegaly patients currently uncontrolled on available SRLs. Furthermore, significant research has been focused in the development of novel delivery modalities (e.g., oral and long acting subcutaneous administration).",
author = "Maria Fleseriu",
year = "2014",
language = "English (US)",
volume = "17",
pages = "329--338",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "96",

}

TY - JOUR

T1 - Advances in the pharmacotherapy of patients with acromegaly

AU - Fleseriu, Maria

PY - 2014

Y1 - 2014

N2 - Acromegaly is a disease characterized by growth hormone (GH) excess originating, in approximately 95% of cases, from a somatotroph pituitary adenoma. Symptomatology and clinical features are due to GH and insulin-like growth factor 1 excess; unfortunately, for most patients diagnosis is delayed by several years. Acromegaly patients' morbidity and mortality are higher than those of the normal population. However, with adequate biochemical control mortality rates can be restored to normal. Tumor size and location, symptoms, comorbidities, and lastly, but not least, patient preference, are all important aspects in treatment decision making, and treatment approach should be individualized. Current therapy includes medical, surgical, and radiation. This review focuses on recent significant developments in medical therapy. There are three major therapeutic drug classes: somatostatin receptor ligands (SRLs), which represent the mainstay of medical therapy, GH receptor blockers, and dopamine agonists. Multi-ligand receptor SRLs such as pasireotide, should increase therapeutic choices for acromegaly patients currently uncontrolled on available SRLs. Furthermore, significant research has been focused in the development of novel delivery modalities (e.g., oral and long acting subcutaneous administration).

AB - Acromegaly is a disease characterized by growth hormone (GH) excess originating, in approximately 95% of cases, from a somatotroph pituitary adenoma. Symptomatology and clinical features are due to GH and insulin-like growth factor 1 excess; unfortunately, for most patients diagnosis is delayed by several years. Acromegaly patients' morbidity and mortality are higher than those of the normal population. However, with adequate biochemical control mortality rates can be restored to normal. Tumor size and location, symptoms, comorbidities, and lastly, but not least, patient preference, are all important aspects in treatment decision making, and treatment approach should be individualized. Current therapy includes medical, surgical, and radiation. This review focuses on recent significant developments in medical therapy. There are three major therapeutic drug classes: somatostatin receptor ligands (SRLs), which represent the mainstay of medical therapy, GH receptor blockers, and dopamine agonists. Multi-ligand receptor SRLs such as pasireotide, should increase therapeutic choices for acromegaly patients currently uncontrolled on available SRLs. Furthermore, significant research has been focused in the development of novel delivery modalities (e.g., oral and long acting subcutaneous administration).

UR - http://www.scopus.com/inward/record.url?scp=84925582130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925582130&partnerID=8YFLogxK

M3 - Article

C2 - 24979253

AN - SCOPUS:84925582130

VL - 17

SP - 329

EP - 338

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 96

ER -